Roivant Sciences Ltd. — Director's Dealing 2026

Jan 1, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2025-12-29

Reporting Person: Sukhatme Mayukh (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-29	Common Shares	M	748358	$12.68	Acquired	19584905	Direct
2025-12-29	Common Shares	S	311873	$21.74	Disposed	19273032	Direct
2025-12-29	Common Shares	J	436485	$21.74	Disposed	18836547	Direct
2025-12-31	Common Shares	M	2449877	$12.68	Acquired	21286424	Direct
2025-12-31	Common Shares	S	1018995	$21.71	Disposed	20267429	Direct
2025-12-31	Common Shares	J	1430882	$21.71	Disposed	18836547	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-29	Stock Option (Right to Buy)	$12.68	M	748358	Disposed	2026-03-31	Common Shares (748358)	Direct
2025-12-31	Stock Option (Right to Buy)	$12.68	M	2449877	Disposed	2026-03-31	Common Shares (2449877)	Direct

Footnotes

F1: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

F2: These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.90, inclusive.

F3: These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.74, inclusive.

F4: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.

F5: Award of stock options to purchase Common Shares that is fully vested.